Cytokinetics Grants 60,465 Stock Options, 40,084 RSUs to 29 New Employees

By Public Technologies
  • Cytokinetics granted stock options covering 60,465 shares and 40,084 restricted stock units on October 15, 2026.
  • The awards cover 29 employees whose employment began in September and October 2026.
  • Restricted stock units vest over three years: 40% on each of the first two grant anniversaries, then 20% on the third.
  • Stock options vest over four years, with 25% vesting after one year; the remainder vests monthly over the next 36 months.
  • The options have a 10-year term. Vesting of both award types requires continued service.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191600PRIMZONEFULLFEED9848689) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.